This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma... The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%... In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved... The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone. However, the three-drug combination improved survival in the relapsed/refractory setting.